Tirzepatide Therapy
What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist marketed as Mounjaro (for diabetes) and Zepbound (for weight loss). It is the first medication to activate both incretin hormone receptors simultaneously, leading to superior weight loss results compared to GLP-1-only medications. Clinical trials showed average weight loss of up to 22.5% of body weight.
Benefits & Uses
Industry-leading weight loss results, superior blood sugar control, improved cardiovascular markers, reduced appetite, potential benefits for fatty liver disease and sleep apnea.
Potential Side Effects
Nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions. Serious but rare risks include pancreatitis, gallbladder problems, and hypoglycemia when combined with insulin.
Find Tirzepatide Providers Near You
Browse 42 providers offering Tirzepatide therapy in our directory.
Browse ProvidersFrequently Asked Questions
Industry-leading weight loss results, superior blood sugar control, improved cardiovascular markers, reduced appetite, potential benefits for fatty liver disease and sleep apnea.
Tirzepatide therapy typically costs between $250 and $550 per month, though prices vary by provider, location, and dosage.
Tirzepatide has an FDA status of "FDA-approved". It has been approved by the FDA for specific indications. Your provider can explain the approved uses and any off-label applications.
Nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions. Serious but rare risks include pancreatitis, gallbladder problems, and hypoglycemia when combined with insulin.
PeptideProbe lists 42 providers offering Tirzepatide therapy. Use our directory to search by location, filter by telehealth availability, and compare providers.
Related Peptides
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.